RNA Interference News and Research

RSS

RNA on leaf surfaces plays role in shaping plant microbiomes

Biologists at Indiana University Bloomington have shown that the surfaces of plant leaves are coated with a diverse array of RNA molecules.

3 Jan 2025

Exploring the protective effects of HSD17B13 in hepatic steatosis

Chronic liver disease (CLD) is a growing global health challenge, accounting for millions of deaths each year. Its major contributors include metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD), and hepatitis C virus infection.

8 Nov 2024

Study links high blood sugar to thrombosis risk in diabetes

A study conducted at the Center for Research on Redox Processes in Biomedicine (Redoxoma) helps understand how high blood sugar (hyperglycemia), one of the manifestations of diabetes, can cause thrombosis.

6 Nov 2024

Researchers uncover how senescent cells can both harm and heal in liver disease

Researchers developed novel genetic tools to trace, ablate, and manipulate p16^Ink4a+^ senescent cells, revealing their distinct roles in liver fibrosis and repair. Senescent macrophages promote fibrosis, while endothelial cells aid in tissue recovery.

7 Oct 2024

Carotenoid phytoene shows potential in slowing Alzheimer’s plaque formation and increasing lifespan

Researchers from the Colour and Food Quality group at the Faculty of Pharmacy (University of Seville), in collaboration with Dr. Marina Ezcurra's group at the University of Kent (UK), have shown that the carotenoid phytoene increases the lifespan of the nematode Caenorhabditis elegans and can slow the onset of paralysis associated with the formation of amyloid plaques in a model of Alzheimer's disease.

26 Sep 2024

New RNA therapy offers hope for mental health

Scientists at Cognigenics have made a significant advance in the field of neuroscience and mental health treatment. Their groundbreaking research, published in Genomic Psychiatry, demonstrates that a new RNA-based therapy called COG-201 can enhance memory and reduce anxiety in animal models.

6 Sep 2024

Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Exploring gene silencing mechanisms for improved RNAi therapeutics

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and cancer.

20 Aug 2024

Antonin (Tony) de Fougerolles appointed as new Chair of etherna

etherna, a leading mRNA technologies company, today announced the appointment of Antonin (Tony) de Fougerolles as Chair. Tony has served as an Independent Board Member since January 2023.

From etherna 10 Jul 2024

New AARF-D award supports Temple researchers to explore synapse function in the aging brain

Late-life depression is a major risk factor for Alzheimer's disease, in particular because it accelerates progression from mild cognitive impairment to dementia.

12 Jun 2024

RNA interference agent plozasiran targets APOC3 for effective mixed hyperlipidemia treatment

Researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia.

31 May 2024

RNA-based therapy shows promise in reducing cholesterol and triglycerides

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

29 May 2024

Study reveals key protein's role in balancing immune response to viral infections

Researchers have revealed the regulatory mechanism of a specific protein that plays a key role in balancing the immune response triggered by viral infections in mammal cells.

18 Apr 2024

New RNA therapy zilebesiran shows promise in lowering blood pressure

Zilebesiran, an RNA interference therapeutic, significantly reduces blood pressure in hypertension patients with a favorable safety profile, offering a potential biannual treatment option.

19 Feb 2024

Discovery of toxic and protective short RNAs associated with Alzheimer's disease and superior memory capacity

Researchers explored how Death Induced by Survival gene Elimination through the analysis of RNA-induced silencing complex-bound short RNAs in Alzheimer's disease models influences neuronal survival and correlates with neurotoxicity in AD.

22 Jan 2024

Short strands of toxic RNAs contribute to brain cell death and DNA damage in Alzheimer's

Alzheimer's disease, which is expected to have affected about 6.7 million patients in the U.S. in 2023, results in a substantial loss of brain cells.

18 Jan 2024

New drug zilebesiran effectively lowers blood pressure for six months, study finds

A single injection of the experimental medication zilebesiran was safe and effective in reducing systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months, as detailed in the Phase 2 of the KARDIA study, reported as late-breaking science today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

Arrayed CRISPR Screening for Revolutionizing Target Discovery

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Kuenzel, Associate Director in the Functional Genomics department at AstraZeneca about the application of arrayed CRISPR screening for target identification and more.

From Society for Laboratory Automation and Screening (SLAS) 27 Sep 2023

Mitochondrial GTP metabolism acts through mitochondrial dynamics factors to regulate reproductive aging

Reproductive aging in Caenorhabditis elegans is regulated through an interaction of the metabolism of mitochondrial guanosine-triphosphate.

18 Sep 2023

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

From AMGEN 1 Sep 2023